Hope for Hard-to-Treat lymphoma: Three-Drug showdown begins
NCT ID NCT07638722
First seen Jun 11, 2026 · Last updated Jun 17, 2026 · Updated 2 times
Summary
This study tests whether a new drug, mosunetuzumab, works better alone or combined with either zanubrutinib or polatuzumab vedotin for people with marginal zone lymphoma that has come back or stopped responding to treatment. About 138 adults will be randomly assigned to one of three treatment groups. The goal is to see which combination leads to more complete remissions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.